drugset
drugset / Trial / NCT06010212

Fruquintinib as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell Carcinoma

NCT06010212 ↗

Phase 1/2 Unknown 36 enrolled The First Affiliated Hospital with Nanjing Medical University
NaSingle-groupOpen-labelTreatment

Summary

This Study is a Single-center, Single-arm, Phase II Clinical Study. The Primary Objective is to Evaluate the Efficacy and Safety of Fruquintinib, Carrelizumab, Paclitaxel Liposomes combined with Nidaplatin as First-line Treatment in Advanced Esophageal squamous cell carcinoma .

Timeline

Start
2023-08-25
Primary completion
2025-08-01
Completion
2026-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Camrelizumab Monoclonal antibody 200 mg Intravenous
Subject Fruquintinib Small molecule 3 mg Oral
Subject Fruquintinib Small molecule 4 mg Oral
Subject Fruquintinib Small molecule 5 mg Oral
Subject Nedaplatin Small molecule 70 mg/m2 Intravenous
Subject Paclitaxel Small molecule 135 mg/m2 Intravenous

Indications

esophageal squamous cell carcinoma